Literature DB >> 17875060

Surgical strategy for non-small cell lung cancer in octogenarians.

Norihiko Ikeda1, Aeru Hayashi, Kentaro Iwasaki, Naohiro Kajiwara, Osamu Uchida, Harubumi Kato.   

Abstract

BACKGROUND AND OBJECTIVES: This study was conducted to determine the optimal surgical strategy for octogenarians with non-small cell lung cancer.
METHODS: An observational study of 73 patients aged 80 years and over who underwent surgery for non-small cell lung cancer. Postoperative survival, mortality and morbidity were analysed.
RESULTS: The age of the patients ranged from 80 to 89 with a mean of 83. Cancer types included adenocarcinoma (n = 46), squamous cell carcinoma (n = 22) and large cell carcinoma (n = 5). Lobectomy was performed in 47 patients and limited surgery in 26. The 5-year survival rate was 57.4% in pathological stage I, 88.9% in stage II and 18.2% in stage III, respectively. The 5-year survival rate of patients with stage I disease treated by limited resection (58.8%) was similar to that of patients treated by lobectomy (54.9%). Limited resection for stage IA showed slightly better survival than lobectomy (69.4% vs 48.2%, P = 0.10), however, lobectomy was superior to limited resection for stage IB (63.2% vs 16.7%, P = 0.07). Postoperative complications occurred in 27 patients (37%) and nine patients (12%) had multiple complications. There were three postoperative deaths (4.1%).
CONCLUSION: The early detection of the disease, hopefully in stage IA enables surgical treatment by limited resection of patients aged 80 years and over. A favourable prognosis as well as low morbidity can be anticipated in such cases.

Entities:  

Mesh:

Year:  2007        PMID: 17875060     DOI: 10.1111/j.1440-1843.2007.01125.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  8 in total

1.  Safety and prognosis of limited surgery for octogenarians with non-small-cell lung cancer.

Authors:  Akira Okada; Tatsuhiko Hirono; Takehiro Watanabe
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-02-12

Review 2.  A decade of advances in treatment of early-stage lung cancer.

Authors:  Luca Paoletti; Nicholas J Pastis; Chadrick E Denlinger; Gerard A Silvestri
Journal:  Clin Chest Med       Date:  2011-10-07       Impact factor: 2.878

3.  Simplified comorbidity score for elderly patients undergoing thoracoscopic surgery for lung cancer.

Authors:  Tomohiro Haruki; Yohei Yurugi; Makoto Wakahara; Yuki Matsuoka; Ken Miwa; Kunio Araki; Yuji Taniguchi; Hiroshige Nakamura
Journal:  Surg Today       Date:  2016-10-03       Impact factor: 2.549

4.  Assessing Survival and Grading the Severity of Complications in Octogenarians Undergoing Pulmonary Lobectomy.

Authors:  Andrew Feczko; Elizabeth McKeown; Jennifer L Wilson; Brian E Louie; Ralph W Aye; Jed A Gorden; Eric Vallières; Alexander S Farivar
Journal:  Can Respir J       Date:  2017-02-08       Impact factor: 2.409

5.  Comparison of Surgical Outcomes and Survival between Octogenarians and Younger Patients after Pulmonary Resection for Stage I Lung Cancer.

Authors:  Seokbeom Hong; Young Kyu Moon; Jae Kil Park
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2018-10-05

6.  Lobectomy versus stereotactic ablative radiotherapy for medically operable patients with stage IA non-small cell lung cancer: A virtual randomized phase III trial stratified by age.

Authors:  Young-Seok Seo; Hak Jae Kim; Hong Gyun Wu; Sun Mi Choi; Samina Park
Journal:  Thorac Cancer       Date:  2019-05-23       Impact factor: 3.500

7.  Survival following segmentectomy or lobectomy in elderly patients with early-stage lung cancer.

Authors:  Yang Zhang; Chongze Yuan; Yawei Zhang; Yihua Sun; Haiquan Chen
Journal:  Oncotarget       Date:  2016-04-05

8.  Virtual randomized study comparing lobectomy and particle beam therapy for clinical stage IA non-small cell lung cancer in operable patients.

Authors:  Young-Seok Seo; Woo-Yoon Park; Si-Wook Kim; Dohun Kim; Byung Jun Min; Won-Dong Kim
Journal:  J Radiat Res       Date:  2021-09-13       Impact factor: 2.724

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.